Novartis (NVS) will cut nearly 2,000 U.S. jobs ahead of the patent loss of top-selling blood...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS) will cut nearly 2,000 U.S. jobs ahead of the patent loss of top-selling blood pressure drug Diovan, and will take a $900M Q4 charge after a clinical trial showed patients taking blood pressure pill Rasilez actually did worse. Rasilez had previously been expected to bring in over $1B in annual sales. (PR)